相关实验视频

Updated: Sep 10, 2025

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

免疫刺激抗体结合剂 (ISAC) 在哪里?

¹Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, Liaoning, China cfu@cmu.edu.cn.

Journal for immunotherapy of cancer

|August 25, 2025

概括

通过激活免疫系统对抗瘤,免疫刺激抗体结合剂 (ISACs) 是有前途的. 然而,临床试验显示有毒性和有效性有限等挑战,需要进一步优化癌症治疗.

科学领域:

癌症学
免疫疗法
药物开发

背景情况:

免疫刺激抗体结合剂 (ISAC) 与抗体药物结合剂 (ADC) 相似,但使用免疫激活剂而不是细胞毒药物.
ISACs旨在增强免疫反应以改善瘤向和消除.
自2021年以来最近的临床试验突出显示了ISAC开发的重大挑战.

研究的目的:

审查免疫刺激抗体结合剂 (ISAC) 作为潜在的癌症治疗药物的现状和挑战.
探索克服ISAC有效性和安全性的策略.
评估ISAC在瘤学的未来潜力,特别是在组合疗法和"冷"瘤中.

主要方法:

关于ISAC的临床试验数据和科学文献的分析.
对优化ISAC设计的策略进行审查,包括有效载荷选择 (TLR7与STING激动剂),链接器稳定性和传递方法.
评估ISAC与现有免疫疗法的协同作用潜力.

主要成果:

临床试验发现了关键挑战,包括有效性有限,全身毒性 (如细胞因子释放综合征) 和抗药抗体生成.
正在探索优化策略,重点关注有效载荷选择,链接技术和本地化交付方法.
尽管有挫折,但ISAC显示出治疗"冷"瘤和增强当前免疫疗法的潜力.

结论:

尽管ISAC面临大量的转化障碍,但其独特的机制在瘤学中具有前景.
进一步完善ISAC设计参数对于临床成功至关重要.
最终ISAC可能成为一种变革性的治疗方式,尤其是在与其他癌症治疗相结合时.

关键词:

抗体与药物结合剂 - - 抗体与药物结合剂免疫调节免疫疗法瘤微环境 - - 瘤微环境

更多相关视频

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates

Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates

Published on: March 6, 2019

相关概念视频

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

Antibody Actions

Antibody Actions

Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...

Humoral Immune Responses

Humoral Immune Responses